PTCT
NASDAQPTC Therapeutics Inc.
Price$65.08+0.32 (+0.49%)
01:30 PM07:45 PM
News · 26 weeks108-15%
2025-11-022026-04-26
Mix4590d
- Insider19(42%)
- SEC Filings10(22%)
- Other9(20%)
- Earnings5(11%)
- Leadership1(2%)
- Analyst1(2%)
Latest news
25 items- SECPTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- PRPTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose -- Continued evidence of favorable safety profile - - Novartis initiated global Phase 3 INVEST-HD study of votoplam -- PTC will host a conference call to discuss results today, April 28, at 4:30 pm ET - WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study, with favorable dose-dependent effects on disease progression for Stage 2 Huntington's disease (HD) patients following 24 months of votoplam treatment compared to a
- PRPTC Therapeutics to Report Results from PIVOT-HD Long Term Extension StudyWARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) will host a webcast conference call today, April 28 at 4:30 p.m. ET to share results from the 24-month interim analysis of the PIVOT-HD long-term extension study of votoplam. PTC's partner Novartis stated on its quarterly earnings call today that long-term extension data are supportive of the now-initiated Novartis Phase 3 INVEST-HD study and Novartis and PTC will assess potential best next steps for the program including further actions with FDA. To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available
- INSIDERCHIEF EXECUTIVE OFFICER Klein Matthew B. sold $202,094 worth of shares (2,850 units at $70.91), decreasing direct ownership by 0.72% to 394,070 units (SEC Form 4) to satisfy withholding tax4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- PRPTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026WARREN, N.J., April 22, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its first quarter 2026 financial results and provide an update on the company's business and outlook on Thursday, May 7, 2026, at 4:30 p.m. ET. To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available on the PTC website for 30 days following the event. To participate via phone, please register in advance here to r
- SECSEC Form DEFA14A filed by PTC Therapeutics Inc.DEFA14A - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- SECSEC Form DEF 14A filed by PTC Therapeutics Inc.DEF 14A - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- PRPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WARREN, N.J., April 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate of 1,155 shares of its common stock and 925 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hire's employment compensation. The inducement grant was approved by PTC's Compensation Committee o
- ANALYSTRaymond James initiated coverage on PTC Therapeutics with a new price targetRaymond James initiated coverage of PTC Therapeutics with a rating of Outperform and set a new price target of $108.00
- INSIDERSEC Form 4 filed by Boulding Mark Elliott4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERSEC Form 4 filed by Golden Lee Scott4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERSEC Form 4 filed by Almstead Neil Gregory4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- SECSEC Form 144 filed by PTC Therapeutics Inc.144 - PTC THERAPEUTICS, INC. (0001070081) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PTC Therapeutics Inc.SCHEDULE 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)
- INSIDERSEC Form 4 filed by Chutter Jessica Caroline4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chutter Jessica Caroline3 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- SECPTC Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- PRPTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of DirectorsWARREN, N.J., March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced the appointment of Jessica Chutter to its Board of Directors. Ms. Chutter is a highly accomplished biotechnology investment banker with an extensive list of achievements over her long tenure at Morgan Stanley, including building and leading the bank's biotechnology franchise. "I have closely followed Jessica's illustrious career, and I am proud to welcome her to PTC's Board of Directors," said Michael Schmertzler, Chairman of the Board of Directors. "Jessica will play an integral role as the Board continues to work with the management team on charting the company's next stage of growth."Ms. Ch
- INSIDERCHIEF EXECUTIVE OFFICER Klein Matthew B. was granted 12,500 shares and sold $170,581 worth of shares (2,662 units at $64.08), increasing direct ownership by 3% to 396,920 units (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- PRPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WARREN, N.J., March 13, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on March 10, 2026, the company approved non-statutory stock options to purchase an aggregate of 14,550 shares of its common stock and 17,515 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on Marc
- INSIDERDirector Okey Stephanie exercised 15,167 shares at a strike of $33.63 and sold $1,061,690 worth of shares (15,167 units at $70.00) (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERCHIEF TECHNICAL OPS OFFICER Almstead Neil Gregory sold $252,823 worth of shares (3,989 units at $63.38) (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDEREVP & CHIEF MEDICAL OFFICER Golden Lee Scott sold $633,800 worth of shares (10,000 units at $63.38), decreasing direct ownership by 11% to 79,944 units (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERDirector Okey Stephanie sold $401,386 worth of shares (6,333 units at $63.38), decreasing direct ownership by 44% to 8,000 units (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDEREXEC. VP AND CLO Boulding Mark Elliott sold $209,763 worth of shares (3,019 units at $69.48), decreasing direct ownership by 3% to 105,212 units (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
PTCT FAQ
7 questionsWhat does PTC Therapeutics Inc. do?
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States...Where does PTCT stock trade?
PTC Therapeutics Inc. (PTCT) is listed on NASDAQ.What sector and industry is PTCT in?
PTC Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did PTC Therapeutics Inc. go public?
PTC Therapeutics Inc. (PTCT) completed its IPO in 2013.What are analysts saying about PTCT?
PTC Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Outperform on 2026-04-10. Recent price targets cluster around $4000.00.What companies are similar to PTCT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare PTCT side-by-side with any of them on Quantisnow.How can I track PTCT on Quantisnow?
Quantisnow aggregates PTC Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PTCT to receive live email and push alerts on every new disclosure.